Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy PAVmed stock | $5.86

Learn how to easily invest in PAVmed stock.

PAVmed Inc is a medical devices business based in the US. PAVmed shares (PAVM) are listed on the NASDAQ and all prices are listed in US Dollars. PAVmed employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in PAVmed

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PAVM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

PAVmed stock price (NASDAQ: PAVM)

Use our graph to track the performance of PAVM stocks over time.

PAVmed shares at a glance

Information last updated 2021-10-23.
Latest market close$5.86
52-week range$1.63 - $9.70
50-day moving average $7.78
200-day moving average $6.28
Wall St. target price$10.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.55

Buy PAVmed shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy PAVmed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

PAVmed price performance over time

Historical closes compared with the close of $5.86 from 2021-10-25

1 week (2021-10-19) -4.56%
1 month (2021-09-24) -36.30%
3 months (2021-07-26) -6.09%
6 months (2021-04-26) 21.33%
1 year (2020-10-26) 210.05%
2 years (2019-10-25) 543.96%
3 years (2018-10-26) 405.17%
5 years (2016-10-22) N/A

PAVmed financials

Gross profit TTM $0
Return on assets TTM -75.54%
Return on equity TTM -259.36%
Profit margin 0%
Book value $0.49
Market capitalisation $484.9 million

TTM: trailing 12 months

Shorting PAVmed shares

There are currently 5.2 million PAVmed shares held short by investors – that's known as PAVmed's "short interest". This figure is 10.1% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting PAVmed shares can be evaluated.

PAVmed's "short interest ratio" (SIR)

PAVmed's "short interest ratio" (SIR) is the quantity of PAVmed shares currently shorted divided by the average quantity of PAVmed shares traded daily (recently around 2.2 million). PAVmed's SIR currently stands at 2.37. In other words for every 100,000 PAVmed shares traded daily on the market, roughly 2370 shares are currently held short.

However PAVmed's short interest can also be evaluated against the total number of PAVmed shares, or, against the total number of tradable PAVmed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PAVmed's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 PAVmed shares in existence, roughly 60 shares are currently held short) or 0.0684% of the tradable shares (for every 100,000 tradable PAVmed shares, roughly 68 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PAVmed.

Find out more about how you can short PAVmed stock.

PAVmed share dividends

We're not expecting PAVmed to pay a dividend over the next 12 months.

PAVmed share price volatility

Over the last 12 months, PAVmed's shares have ranged in value from as little as $1.63 up to $9.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PAVmed's is 0.2296. This would suggest that PAVmed's shares are less volatile than average (for this exchange).

PAVmed overview

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015.

Frequently asked questions

What percentage of PAVmed is owned by insiders or institutions?
Currently 10.873% of PAVmed shares are held by insiders and 25.063% by institutions.
How many people work for PAVmed?
Latest data suggests 25 work at PAVmed.
When does the fiscal year end for PAVmed?
PAVmed's fiscal year ends in December.
Where is PAVmed based?
PAVmed's address is: One Grand Central Place, New York, NY, United States, 10165
What is PAVmed's ISIN number?
PAVmed's international securities identification number is: US70387R1068
What is PAVmed's CUSIP number?
PAVmed's Committee on Uniform Securities Identification Procedures number is: 70387R106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site